Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Welcome to the Globus Medical's fourth quarter and full year 2024 earnings call. At this time, all lines will be on mute, and ...

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price ...

For the quarter ended December 2024, Globus Medical (GMED) reported revenue of $657.29 million, up 6.6% over the same period last year. EPS came in at $0.84, compared to $0.60 in the year-ago quarter.

Globus Medical saw fourth quarter net sales grow 6.6% year over year, and full year sales leapt 60.6%, according to financial results posted Feb. 20.

Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results , with sales up 6.6% year on year to $657.3 ...

Reports Q4 revenue $657.29M, consensus $646.19M. “I’m proud of our team at Globus Medical (GMED), delivering incredible results for 2024. We ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...